Natera, Inc.(NTRA) - Stock detail

Natera, Inc.

US
NTRA
Natera, Inc.(Listing date: 07/02/2015)

Natera, Inc. was incorporated in Delaware in January 2007. The company is a diagnostic company with proprietary molecular and bioinformatics technologies that it is applying to transform disease management worldwide. The company's cell-free DNA (cfDNA) technology combines novel molecular analytical methods that can reliably measure many informative regions across the entire genome from samples as small as a single cell, as well as statistical algorithms that incorporate data provided by the broader scientific community to identify genetic variations covering a wide range of serious diseases with high precision and high coverage. The company's goal is to make personalized genetic testing and diagnosis part of the standard of care for protecting health and inform earlier and more targeted interventions to help achieve longer, healthier lives.

AI Trading DecisionSell
Generated at:2026-03-13 17:50:07
Analysis based on comprehensive technical and fundamental data including moving averages (5-day: $202.70, 10-day: $209.41, 20-day: $223.95, 60-day: $199.08), MACD indicators, valuation metrics, and market performance data up to February 2026
Summary

Sell recommendation for Natera, Inc. (NTRA) with target price of $165.00 and stop-loss at $185.00. Confidence level is 0.78 with high risk score of 0.72 based on concerning technical breakdown, unsustainable valuation despite growth, and macroeconomic sensitivity.

Operation strategy
  • Current holders should implement immediate stop-loss orders at $185
  • Use any technical bounces toward $200-202 to reduce exposure
  • New buyers should avoid entering until the stock stabilizes above $214 with improving technical indicators

Core Support

Reasoning summary
  • The stock is in a confirmed downtrend, trading below all major moving averages with accelerating bearish momentum
  • MACD histogram at -5.8577 indicates increasing selling pressure with high-volume decline suggesting institutional distribution
  • Valuation multiples are stratospheric for a company with negative earnings despite impressive revenue growth
  • Current valuation shows P/S 11.55x and P/B 25.42x with trailing PE -103.56 and forward PE -168.14
  • $208 million net loss in 2025 contradicts the bullish narrative of sustainable profitability
  • Stock's 8.3% single-day drop on February 27 demonstrates vulnerability to macroeconomic conditions
  • Immediate technical support at lower Bollinger Band ($188.49) has been breached with next support at estimated average cost basis of $165.82
  • Fundamental strengths like Zenith Genomics launch and Signatera clinical data are overwhelmed by technical weakness and valuation concerns